Breast cancer is the leading cause of cancer death among women worldwide. The vast majority of breast cancers are carcinomas that originate from cells lining the milk-forming ducts of the mammary gland. The molecular subtypes of breast cancer, which are based on the presence or absence of hormone receptors (estrogen and progesterone subtypes) and human epidermal growth factor receptor-2 (HER2), include: hormone receptor positive and HER2 negative (luminal A subtype), hormone receptor positive and HER2 positive (luminal B subtype), hormone receptor negative and HER2 positive (HER2 positive), and hormone receptor negative and HER2 negative (basal-like or triple-negative breast cancers (TNBCs)). Hormone receptor positive breast cancers are largely driven by the estrogen/ER pathway. In HER2 positive breast tumours, HER2 activates the PI3K/AKT and the RAS/RAF/MAPK pathways, and stimulate cell growth, survival and differentiation. In patients suffering from TNBC, the deregulation of various signalling pathways (Notch and Wnt/beta-catenin), EGFR protein have been confirmed. In the case of breast cancer only 8% of all cancers are hereditary, a phenomenon linked to genetic changes in BRCA1 or BRCA2. Somatic mutations in only three genes (TP53, PIK3CA and GATA3) occurred at >10% incidence across all breast cancers.

Human Diseases; Cancer: specific types

nt06210  ERK signaling
nt06214  PI3K signaling
nt06215  WNT signaling
nt06216  NOTCH signaling
nt06227  NR signaling
nt06230  Cell cycle G1/S
nt06240  Transcription
nt06260  Colorectal cancer
nt06261  Gastric cancer
nt06262  Pancreatic cancer
nt06263  Hepatocellular carcinoma
nt06265  Bladder cancer
nt06266  Non-small cell lung cancer
nt06267  Small cell lung cancer
nt06268  Melanoma
nt06269  Basal cell carcinoma
nt06270  Breast cancer
nt06271  Endometrial cancer
nt06272  Prostate cancer
nt06273  Glioma
nt06274  Thyroid cancer
nt06276  Chronic myeloid leukemia

Homo sapiens (human) [GN:hsa]

PMID:24649067

Zhang MH, Man HT, Zhao XD, Dong N, Ma SL

Estrogen receptor-positive breast cancer molecular signatures and therapeutic potentials (Review).

Biomed Rep 2:41-52 (2014)
DOI:10.3892/br.2013.187

PMID:27390604

Dai X, Xiang L, Li T, Bai Z

Cancer Hallmarks, Biomarkers and Breast Cancer Molecular Subtypes.

J Cancer 7:1281-94 (2016)
DOI:10.7150/jca.13141

PMID:20436504

Schnitt SJ

Classification and prognosis of invasive breast cancer: from morphology to molecular taxonomy.

Mod Pathol 23 Suppl 2:S60-4 (2010)
DOI:10.1038/modpathol.2010.33

PMID:23000897

Comprehensive molecular portraits of human breast tumours.

Nature 490:61-70 (2012)
DOI:10.1038/nature11412

PMID:22178455

Eroles P, Bosch A, Perez-Fidalgo JA, Lluch A

Molecular biology in breast cancer: intrinsic subtypes and signaling pathways.

Cancer Treat Rev 38:698-707 (2012)
DOI:10.1016/j.ctrv.2011.11.005

Karamouzis MV, Papavassiliou KA, Adamopoulos C, Papavassiliou AG.

Targeting androgen/estrogen receptors crosstalk in cancer

Trends in Cancer 2(1):35-48 (2016)
DOI:10.1016/j.trecan.2015.12.001

Sharp A, Harper-Wynne C.

Treatment of advanced breast cancer (ABC): the expanding landscape of targeted therapies

J Cancer Biol Res 2(1):1036 (2014)

PMID:24596345

Byler S, Goldgar S, Heerboth S, Leary M, Housman G, Moulton K, Sarkar S

Genetic and epigenetic aspects of breast cancer progression and therapy.

Anticancer Res 34:1071-7 (2014)

PMID:23988612

Mohamed A, Krajewski K, Cakar B, Ma CX

Targeted therapy for breast cancer.

Am J Pathol 183:1096-112 (2013)
DOI:10.1016/j.ajpath.2013.07.005

PMID:22722193

Ellis MJ, Ding L, Shen D, Luo J, Suman VJ, Wallis JW, Van Tine BA, Hoog J, Goiffon RJ, Goldstein TC, Ng S, Lin L, Crowder R, Snider J, Ballman K, Weber J, Chen K, Koboldt DC, Kandoth C, Schierding WS, McMichael JF, Miller CA, Lu C, Harris CC, McLellan MD, Wendl MC, DeSchryver K, Allred DC, Esserman L, Unzeitig G, Margenthaler J, Babiera GV, Marcom PK, Guenther JM, Leitch M, Hunt K, Olson J, Tao Y, Maher CA, Fulton LL, Fulton RS, Harrison M, Oberkfell B, Du F, Demeter R, Vickery TL, Elhammali A, Piwnica-Worms H, McDonald S, Watson M, Dooling DJ, Ota D, Chang LW, Bose R, Ley TJ, Piwnica-Worms D, Stuart JM, Wilson RK, Mardis ER

Whole-genome analysis informs breast cancer response to aromatase inhibition.

Nature 486:353-60 (2012)
DOI:10.1038/nature11143

PMID:25907219

Ma CX, Reinert T, Chmielewska I, Ellis MJ

Mechanisms of aromatase inhibitor resistance.

Nat Rev Cancer 15:261-75 (2015)
DOI:10.1038/nrc3920

PMID:16113099

Butt AJ, McNeil CM, Musgrove EA, Sutherland RL

Downstream targets of growth factor and oestrogen signalling and endocrine resistance: the potential roles of c-Myc, cyclin D1 and cyclin E.

Endocr Relat Cancer 12 Suppl 1:S47-59 (2005)
DOI:10.1677/erc.1.00993

PMID:24111892

Dasgupta S, Lonard DM, O'Malley BW

Nuclear receptor coactivators: master regulators of human health and disease.

Annu Rev Med 65:279-92 (2014)
DOI:10.1146/annurev-med-051812-145316

PMID:23702927

Brisken C

Progesterone signalling in breast cancer: a neglected hormone coming into the limelight.

Nat Rev Cancer 13:385-96 (2013)
DOI:10.1038/nrc3518

PMID:20087430

Scarpin KM, Graham JD, Mote PA, Clarke CL

Progesterone action in human tissues: regulation by progesterone receptor (PR) isoform expression, nuclear positioning and coregulator expression.

Nucl Recept Signal 7:e009 (2009)
DOI:10.1621/nrs.07009

PMID:24291072

Knutson TP, Lange CA

Tracking progesterone receptor-mediated actions in breast cancer.

Pharmacol Ther 142:114-25 (2014)
DOI:10.1016/j.pharmthera.2013.11.010

PMID:25544707

Dittrich A, Gautrey H, Browell D, Tyson-Capper A

The HER2 Signaling Network in Breast Cancer--Like a Spider in its Web.

J Mammary Gland Biol Neoplasia 19:253-70 (2014)
DOI:10.1007/s10911-014-9329-5

PMID:21965336

Higgins MJ, Baselga J

Targeted therapies for breast cancer.

J Clin Invest 121:3797-803 (2011)
DOI:10.1172/JCI57152

PMID:26028978

Mukohara T

PI3K mutations in breast cancer: prognostic and therapeutic implications.

Breast Cancer (Dove Med Press) 7:111-23 (2015)
DOI:10.2147/BCTT.S60696

PMID:19088017

Schneider BP, Winer EP, Foulkes WD, Garber J, Perou CM, Richardson A, Sledge GW, Carey LA

Triple-negative breast cancer: risk factors to potential targets.

Clin Cancer Res 14:8010-8 (2008)
DOI:10.1158/1078-0432.CCR-08-1208

PMID:21898546

King TD, Suto MJ, Li Y

The Wnt/beta-catenin signaling pathway: a potential therapeutic target in the treatment of triple negative breast cancer.

J Cell Biochem 113:13-8 (2012)
DOI:10.1002/jcb.23350

PMID:11737884

Brown AM

Wnt signaling in breast cancer: have we come full circle?

Breast Cancer Res 3:351-5 (2001)
DOI:10.1186/bcr321

PMID:21076461

Geyer FC, Lacroix-Triki M, Savage K, Arnedos M, Lambros MB, MacKay A, Natrajan R, Reis-Filho JS

beta-Catenin pathway activation in breast cancer is associated with triple-negative phenotype but not with CTNNB1 mutation.

Mod Pathol 24:209-31 (2011)
DOI:10.1038/modpathol.2010.205

PMID:20971825

Al-Hussaini H, Subramanyam D, Reedijk M, Sridhar SS

Notch signaling pathway as a therapeutic target in breast cancer.

Mol Cancer Ther 10:9-15 (2011)
DOI:10.1158/1535-7163.MCT-10-0677

PMID:26968398

Rangel MC, Bertolette D, Castro NP, Klauzinska M, Cuttitta F, Salomon DS

Developmental signaling pathways regulating mammary stem cells and contributing to the etiology of triple-negative breast cancer.

Breast Cancer Res Treat 156:211-26 (2016)
DOI:10.1007/s10549-016-3746-7

PMID:26040571

Jamdade VS, Sethi N, Mundhe NA, Kumar P, Lahkar M, Sinha N

Therapeutic targets of triple-negative breast cancer: a review.

Br J Pharmacol 172:4228-37 (2015)
DOI:10.1111/bph.13211

PMID:23196196

Karamboulas C, Ailles L

Developmental signaling pathways in cancer stem cells of solid tumors.

Biochim Biophys Acta 1830:2481-95 (2013)
DOI:10.1016/j.bbagen.2012.11.008

PMID:23881035

Ignatiadis M, Sotiriou C

Luminal breast cancer: from biology to treatment.

Nat Rev Clin Oncol 10:494-506 (2013)
DOI:10.1038/nrclinonc.2013.124

PMID:25013431

Shin SJ, Gong G, Lee HJ, Kang J, Bae YK, Lee A, Cho EY, Lee JS, Suh KS, Lee DW, Jung WH

Positive expression of insulin-like growth factor-1 receptor is associated with a positive hormone receptor status and a favorable prognosis in breast cancer.

J Breast Cancer 17:113-20 (2014)
DOI:10.4048/jbc.2014.17.2.113

PMID:11879567

Gasco M, Shami S, Crook T

The p53 pathway in breast cancer.

Breast Cancer Res 4:70-6 (2002)
DOI:10.1186/bcr426

PMID:15343273

Narod SA, Foulkes WD

BRCA1 and BRCA2: 1994 and beyond.

Nat Rev Cancer 4:665-76 (2004)
DOI:10.1038/nrc1431